Maricann Secures $42,500,000 Non-Dilutive Financing for Further German Expansion
TORONTO, May 04, 2017 (GLOBE NEWSWIRE) -- Maricann Group Inc. (CSE:MARI) (Maricann or the "Company") is pleased to announce that Maricann has secured $42,500,000 in non-dilutive financing to further expand production in Germany.
The $42,500,000 non-dilutive financing comes from The Green Streaming Finance Company of Canada Inc. a Vancouver-based company that provides non-equity financing solutions for cannabis producers. The streaming payment will be made in return for the right to purchase 20% of production at an all in cost + 10% from expansion funded by Green Streaming in Germany. "We are pleased to be funding Maricann and their expansion efforts in Germany. This is a win-win relationship for Maricann and Green Streaming Finance, with no dilution to Maricann shareholders and a stable, reliable, renewable stream of revenue to Green Stream Finance from a proven producer of medicinal cannabis," said Donald McInnes, founder of Green Streaming Finance. Under the terms of the agreement, Maricann will receive investment in two tranches, $15,000,000 and a $27,500,000.
This financing will fully fund the planned 150,000 sq. ft (13,935 square meters) expansion of cultivation operations in its Ebersbach Facility and an additional 250,000 sq. ft. (23,255 sq. m.) of expansion in a two tiered cultivation plan, as well as an outdoor hemp farm from which Maricann will derive high CBD content active pharmaceutical ingredients. The Ebersbach facility (West of Dresden) is a former Cargill plant constructed 20 years ago at a cost of 80 million EUR at that time. The facility is comprised of multiple individual clean rooms that are ideal for cultivation of cannabis. "The Ebersbach facility offers Maricann a significant advantage in cost of overall construction and speed to market. The infrastructure for cultivation of cannabis in an indoor secured environment is already in place. We simply need to add the fertigation system, lights and benches for growing, and then can be operational. Our competitors are spending north of $70,000,000 CAD for facilities with less than 1/3 the footprint of our Ebersbach location. To construct a similar facility today, the estimated cost would be over 120 million EUR. Maricann entered into a reservation agreement to purchase the facility for a total price of 3,410,000 EUR at closing," said Benjamin Ward, CEO.
About Maricann Group Inc.
Maricann is a vertically integrated producer and distributor of marijuana for medical purposes. The company was founded in 2013 and is based in Langton, Ontario, where it operates a medicinal cannabis cultivation, extraction and distribution business under federal licence from the Government of Canada. Maricann, which has federal licences to cultivate, process and distribute cannabis, services a patient base with more than 8,000 total registered patients since inception. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a fully funded 217,000 sq. ft. (20,159 sq. m), to support existing and future patient growth. Maricann GmbH is a 95% owned subsidiary of Maricann Netherlands BV, a 100% wholly owned subsidiary of Maricann Group Inc.
- April 2013, Maricann Inc. is founded in Langton, Ontario, a well-established agricultural region in southwestern Ontario
- March 2014, Maricann Inc. obtains its Health Canada licence to cultivate plants
- December 2014, Maricann Inc. obtains its Health Canada licence to sell dried cannabis
- January 2015, first dried cannabis sale
- September 2016, Maricann Inc. earns its Health Canada licence to sell cannabis extracts
- October 2016, first sale of extracted cannabis
- December 2016, Maricann Inc. raises $22.5 million in private capital
- January 2017, commences sale of clones
- February 2017, Maricann Inc. raises $10 million in private capital
- April 24, 2017, first day of trading on the CSE
- April 28, 2017, announces Advisory Board of German subsidiary.
For more information about Maricann please visit our website at www.maricann.ca
Forward Looking Information
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release. This news release contains certain forward-looking statements that reflect the current views and/or expectations of management with respect to performance, business and future events, including but not limited to express or implied statements and assumptions regarding the Company's business and operations. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business and the industry and markets in which the Company operates. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Accordingly, readers should not place undue reliance on forward-looking statements and information, which are qualified in their entirety by this cautionary statement. The Company does not undertake any obligations to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law.
VP Investor Relations
Maricann Group Inc. (C.MARI)
845 Harrington Court, Unit 3
Burlington Ontario L7N 3P3
Dial Toll Free in North America:
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Maricann Group Inc. via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Oxford Immunotec to Present at the 29th Annual Piper Jaffray Healthcare Conference21.11.2017 15:15 | Pressmeddelande
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that Peter Wrighton-Smith, Chief Executive Officer, will present at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28th, at 12:00 p.m. EST. The conference will be held at the Lotte New York Palace. A live webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.oxfordimmunotec.com. A webcast replay will be available approximately two hours after the live presentation and will be archived on the website for approximately 90 days. About Oxford Immunotec Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and comme
OmniComm Systems Signs Letter of Intent to Acquire Certain Assets of Algorithm and its Subsidiary Algorics21.11.2017 14:00 | Pressmeddelande
Acquisition Will Expand OmniComm's Product Line With Data Analytics and Risk-Based Monitoring Solutions FORT LAUDERDALE, Fla., Nov. 21, 2017 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OTCQX:OMCM), a leading global provider of clinical data management technology, and Algorithm, Inc. and its subsidiaries Algorics Ltd. and Algorithm Informatics Pvt. Ltd. (collectively, "Algorics"), have signed a letter of intent ("LOI"), under which OmniComm will acquire certain assets and assume certain liabilities of Algorics, a provider of clinical analytics solutions and software. By combining forces, the companies expect increased operating efficiency, strengthened traction in the maturing risk-based approach solution area, new marketing opportunities and an expanded portfolio of electronic data capture (EDC) solutions for the global clinical trials industry. The transaction would also provide OmniComm with an office in India, a country of growing importance in t
CrownBio's Translatable FATZO Model Utilized in Eli Lilly's Preclinical Type 2 Diabetes Research Programs21.11.2017 14:00 | Pressmeddelande
SANTA CLARA, Calif., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the publication of two new papers. These joint publications illustrate the utility of Crown Bioscience's proprietary FATZO model as a model for obesity and type 2 diabetes in preclinical studies. The research conducted by Crown Bioscience, Eli Lilly and Company and Ball State University was published in two PLOS ONE papers: Peterson et al. Glucose dysregulation and response to common anti-diabetic agents in the FATZO/Pco model PLOS One 2017;12 (6):e0179856, https://doi.org/10.1371/journal.pone.0179856 Droz et al. Correlation of disease severity with body weight and high fat diet in the FATZO/Pco model PLOS One 2017;1
Port Moresby Stock Exchange (POMSoX) Launches New Nasdaq Trading System21.11.2017 11:31 | Pressmeddelande
NEW YORK and PORT MORESBY, Papua New Guinea, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Nasdaq Inc. (NASDAQ:NDAQ) and the Port Moresby Stock Exchange (POMSoX) have announced that POMSoX has gone live with the widely deployed Nasdaq Matching Engine that operates on the Nasdaq Financial Framework platform. The launch of the new trading platform is a result of an upgrade from previous Nasdaq trading technology. The new trading engine will handle the trading of equities in the Papua New Guinea market. POMSoX has been a customer of Nasdaq since 1999. "The Nasdaq trading platform will allow significant innovation in terms of market design and market offerings," said Johnson Kalo, a POMSoX board member said. "We believe the platform will provide strong support for future growth in the PNG market and provide new business opportunities in areas such as market data distribution." "We are pleased to continue to support POMSoX, a longstanding Nasdaq customer," said Robert Frojd, Regional Man
CloudCraze Joins the Pledge 1% Movement, Makes Commitment to Philanthropic Leadership21.11.2017 08:00 | Pressmeddelande
CloudCraze will leverage profit and employee time to improve communities around the world LONDON, Nov. 21, 2017 (GLOBE NEWSWIRE) -- CloudCraze, the enterprise B2B commerce platform built natively on Salesforce, has joined Pledge 1%, a corporate philanthropy movement dedicated to making the community a key stakeholder in every business. Spearheaded by Atlassian, Rally, Salesforce and Tides, Pledge 1% empowers companies to donate 1% of product, 1% of equity, 1% of profit or 1% of employee time to improve communities around the world. CloudCraze is joining an impressive network of entrepreneurs and companies across the globe that have committed to philanthropic efforts through the Pledge 1% movement. By pledging 1% of its profit and employee time, CloudCraze is demonstrating a commitment to philanthropic leadership. "We are incredibly excited that CloudCraze has taken the pledge," said Amy Lesnick, chief executive of Pledge 1%. "CloudCraze can play a pivotal role i
HemChecks avläsare kalibrerad med toppresultat - Regulatorisk20.11.2017 16:18 | Pressmeddelande
HemChecks avläsare kalibrerad med toppresultat Det medicintekniska bolaget HemCheck, som utvecklar ett patientnära test för detektion av hemolys, kan idag meddela att den digitala avläsare som utgör en del av bolagets produktkoncept Helge, kalibrerats med mycket gott resultat. Detta skedde genom studier i egen regi. Avläsaren kan nu färdigställas och produktkonceptet kommer därmed ett steg närmare CE-märkning. Som ett led i att färdigställa bolagets produktkoncept Helge har HemCheck under hösten utfört studier i egen regi med hjälp av blod från frivilliga bloddonatorer. Syftet var att kalibrera avläsaren och på så sätt möjliggöra en patientnära avläsning av hemolys, det vill säga redan på ett tidigt stadium avgöra om blodprovet är användbart och kan ska skickas till analys. -Enkelt utryckt har vi lärt avläsaren att mäta hemolys på våra engångstester. Det är en viktig milstolpe och en stor framgång. Nu känner vi oss redo
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum